When InO says no: understanding escape
Author:
Affiliation:
1. 1Princess Máxima Center for Pediatric Oncology
2. 2Erasmus MC-Sophia Children’s Hospital
Publisher
American Society of Hematology
Link
https://ashpublications.org/blood/article-pdf/144/1/2/2233507/blood_bld-2024-024713-c-main.pdf
Reference9 articles.
1. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL;Zhao;Blood,2024
2. Mechanisms of and approaches to overcoming resistance to immunotherapy;Schultz;Hematology Am Soc Hematol Educ Program,2019
3. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial;Pennesi;Leukemia,2022
4. Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed Immunotherapies;Zheng;Blood Cancer Discov,2022
5. CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia;Wintering;Blood Adv,2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3